Has Rashmi Advani, MD received payments from drug or device companies?

Yes. Drug and device makers reported $63,358 in general payments to Rashmi Advani, MD across 124 transactions between 2019–2025. Most Open Payments records nationally are meals worth under $20; a reported payment is not evidence of wrongdoing.

Does a payment mean Rashmi Advani, MD did something wrong?

No. Federal law requires drug and device makers to report almost every transfer of value to a physician, including a $14 sandwich at a lunch presentation. Consulting fees, research funding and royalties to device inventors are ordinary, legal parts of medicine. This site reports what was disclosed; it makes no allegation.

Where does this information about Rashmi Advani, MD come from?

The U.S. Centers for Medicare & Medicaid Services. Payments come from Open Payments, published under the Physician Payments Sunshine Act. Billing and prescribing figures come from the Medicare Physician & Other Practitioners and Part D Prescriber public use files for 2024.

Rashmi Advani, MD

Gastroenterology · Bellmore, NYNPI 1902253958

Payments from drug & device makers

What this record shows

The money is spread across several categories — speaking fees (50.7%), grants and travel and lodging — rather than concentrated in one kind of arrangement. Boston Scientific accounts for 90.7% of it on its own, with 18 other manufacturers making up the rest. Among gastroenterology clinicians in NY with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$63,358in general payments, 2019–2025

Across 124 payments — averaging $510.95 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

Boston Scientific$57K
Medtronic$3K
Ovesco Endoscopy USA, Inc.$647
Olympus America Inc.$385
Fujifilm Healthcare Americas Corporation$238
Novo Nordisk$197
plus $1K from 13 others

What the payments were for

Speaking & faculty fees$32,15051%
Grants$20,00032%
Travel & lodging$6,19610%
Food & beverage$5,0128%

General payments by program year

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

Company	Payments	Total
Boston Scientific	81	$57,441
Medtronic	1	$3,150
Ovesco Endoscopy USA, Inc.	1	$647
Olympus America Inc.	7	$385
Fujifilm Healthcare Americas Corporation	3	$238
Novo Nordisk	6	$197
AbbVie	7	$168
3-d Matrix, Inc.	1	$167
Olympus Corporation Of The Americas	1	$162
Madrigal Pharmaceuticals	1	$150
Janssen Scientific Affairs, LLC	1	$142
Cook Medical LLC	2	$138
AstraZeneca	1	$135
Johnson & Johnson	5	$101
Phathom Pharmaceuticals, Inc.	2	$50
Conmed Corporation	1	$30
Redhill Biopharma Inc.	1	$23
Nestle Healthcare Nutrition Inc.	1	$19
Takeda Pharmaceuticals U.S.A., Inc.	1	$13

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

APOLLO ESG System$13,178
ORBERA Intragastric Balloon System$11,000
OverStitch NXT Endoscopic Suturing System$5,000
Cool-tip$3,150
GENERAL - THERAPIES$2,411
EXALT Model D$1,820
GENERAL ENDOCHOICE$1,194
OverStitch Endoscopic Suturing System$663
VISIGLIDE$279
Single Use Electrosurgical Knife KD-655$162
Single Use Aspiration Needle NA-U200H$162
DISPOSABLE DISTAL ATTACHMENT$162
Olympus$162
REZDIFFRA$150
STELARA$142
AXIOS$140
EndoClot SIS$136
IMFINZI$135
ECHOTIP INSIGHT$134

How this compares

$63,358 in reported general payments places this provider in the 90th percentile of 1,682 gastroenterology providers in New York.

See all gastroenterology providers in New York →

Medicare billing

Part B allowed, 2024

$85,410

Medicare patients

155

Services billed

520

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

Drug	Claims	Cost to plans & patients
Pantoprazole Sodium	44	$330
Ondansetron Hcl	12	$231
Omeprazole	40	$153
Famotidine	14	$76

Paid to pharmacies, not to this prescriber.

Other gastroenterology in Bellmore

David Carr LockeNew York$2M
Arthur KornbluthNew York$1.9M
Maya SrivastavaWilliamsville$1.8M
Melissa PalmerPlainview$1M
Sonal KumarNew York$1M
David PoppersNew York$939K
Ellen ScherlNew York$857K
Bruce SandsNew York$810K
Jean Frederick ColombelNew York$786K
Seth GrossNew York$624K

See the full list for New York →

Where these figures come from

Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
Identity: NPPES NPI Registry, July 2026.

Is this you, or does something look wrong? →